(VIANEWS) – WALLENIUS WILHELMS (WAWI.OL), ALTRI SGPS (ALTR.LS), NORBIT (NORBT.OL) are the highest sales growth and return on equity stocks on this list.
Here is a list of stocks with an above 5% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?
1. WALLENIUS WILHELMS (WAWI.OL)
1027.3% sales growth and 25.2% return on equity
Wallenius Wilhelmsen ASA, together with its subsidiaries, engages in the logistics and transportation business worldwide. It operates through three segments: Shipping Services, Logistics Services, and Government Services. The company provides liner services through a fleet of modern and versatile RoRo vessels, which carry a mix of products, such as auto, construction, mining, agriculture machinery, and breakbulk products. In addition, it offers inland transportation services, as well as operates vehicle and equipment processing centers and inland distribution networks. The company serves agriculture, automotive, aviation, boats and yachts, breakbulk, commercial vehicles, construction, machinery and machine tools, mining, oil and gas, power and energy, and rail industries. It operates approximately 125 vessels servicing 15 trade routes, 66 processing centers, and 8 marine terminals. Wallenius Wilhelmsen ASA was founded in 1861 and is based in Lysaker, Norway.
Earnings Per Share
As for profitability, WALLENIUS WILHELMS has a trailing twelve months EPS of kr22.41.
PE Ratio
WALLENIUS WILHELMS has a trailing twelve months price to earnings ratio of 4.36. Meaning, the purchaser of the share is investing kr4.36 for every norwegian krone of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 25.2%.
Growth Estimates Quarters
The company’s growth estimates for the current quarter and the next is 795.7% and 854.3%, respectively.
Moving Average
WALLENIUS WILHELMS’s value is below its 50-day moving average of kr104.30 and below its 200-day moving average of kr99.54.
More news about WALLENIUS WILHELMS.
2. ALTRI SGPS (ALTR.LS)
39.3% sales growth and 18.52% return on equity
Altri, SGPS, S.A. produces and sells cellulosic fibers and energy in Portugal and internationally. The company produces pulp products for various application including production of paper, tissue, and printing and writing papers; and dissolving pulp for use of textile production. It is also involved timber commercialization; forest management; production of forest-based renewable energy, such as industrial cogeneration from black liquor and biomass; real estate activities; and production of plants in nurseries, as well as the provision of services related with forests and landscapes. The company was incorporated in 2005 and is headquartered in Porto, Portugal.
Earnings Per Share
As for profitability, ALTRI SGPS has a trailing twelve months EPS of €0.37.
PE Ratio
ALTRI SGPS has a trailing twelve months price to earnings ratio of 12.8. Meaning, the purchaser of the share is investing €12.8 for every euro of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 18.52%.
Volume
Today’s last reported volume for ALTRI SGPS is 70132 which is 84.22% below its average volume of 444597.
Dividend Yield
As claimed by Morningstar, Inc., the next dividend payment is on May 21, 2024, the estimated forward annual dividend rate is 0.25 and the estimated forward annual dividend yield is 5.1%.
Moving Average
ALTRI SGPS’s value is under its 50-day moving average of €5.24 and below its 200-day moving average of €4.90.
Sales Growth
ALTRI SGPS’s sales growth for the next quarter is 39.3%.
More news about ALTRI SGPS.
3. NORBIT (NORBT.OL)
35% sales growth and 21.94% return on equity
Norbit ASA provides technology products and solutions. It operates through Oceans, Connectivity, and Product Innovation and Realization segments. The company offers multibeam sonar systems, including integrated bathymetric systems, bathymetry systems, advanced monitoring systems for dredging, construction and renewables, forward looking wide area imaging, advanced imaging systems for obstacle avoidance/MCM, and above water laser products under the NORBIT WINGHEAD, NORBIT WBMS, NORBIT NORdredge, and NORBIT FLS names; customized cable assemblies, electromechanical box builds, and operational solutions; SeaCOP, a sensor integration platform and user interface common operational picture for emergency response; SECurus provides thermal and daylight stabilized camera solutions; SeaView, which offers thermal and daylight, pan, tilt, and zoom for environmental monitoring, and security and general surveillance; and SeaDarQ, a radar processing solution. It also provides sensing solutions for detecting threats at sea plus waterside security above and below the surface; FCL600, an underwater light solution for aquaculture industry; iData, which offers vehicle monitoring, telematics services, and fleet management for asset and vehicle management; and dedicated short-range communication technology for traffic system and vehicle application. In addition, the company offers research and development services, and contract manufacturing to industrial customers; and sells products based on proprietary technology, including special instrumentation n based on radar, radio frequency, and embedded signal processing technology. Norbit ASA was founded in 1995 and is headquartered in Trondheim, Norway.
Earnings Per Share
As for profitability, NORBIT has a trailing twelve months EPS of kr2.72.
PE Ratio
NORBIT has a trailing twelve months price to earnings ratio of 28.6. Meaning, the purchaser of the share is investing kr28.6 for every norwegian krone of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 21.94%.
Dividend Yield
As maintained by Morningstar, Inc., the next dividend payment is on May 7, 2024, the estimated forward annual dividend rate is 2.55 and the estimated forward annual dividend yield is 3.32%.
Sales Growth
NORBIT’s sales growth is negative 3.5% for the ongoing quarter and 35% for the next.
Moving Average
NORBIT’s value is above its 50-day moving average of kr76.24 and way above its 200-day moving average of kr65.35.
More news about NORBIT.
4. ASM INTERNATIONAL (ASM.AS)
26.5% sales growth and 17.12% return on equity
ASM International NV, together with its subsidiaries, engages in the research, development, manufacture, marketing, and servicing of equipment and materials used to produce semiconductor devices in Europe, the United States, and Asia. The company's products include wafer processing deposition systems for atomic layer deposition (ALD), epitaxy, silicon carbide, plasma enhanced chemical vapor deposition (PECVD), and vertical furnace systems, including low pressure chemical vapor deposition (LPCVD), diffusion, and oxidation products, as well as provides spare parts and support services. It also manufactures and sells equipment, which is used in wafer processing, encompassing the fabrication steps in which silicon wafers are layered with semiconductor devices. The company offers its products to semiconductor manufacturers. The company was formerly known as Advanced Semiconductor Materials International NV. ASM International NV was incorporated in 1968 and is headquartered in Almere, the Netherlands.
Earnings Per Share
As for profitability, ASM INTERNATIONAL has a trailing twelve months EPS of €11.2.
PE Ratio
ASM INTERNATIONAL has a trailing twelve months price to earnings ratio of 50.59. Meaning, the purchaser of the share is investing €50.59 for every euro of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 17.12%.
Volume
Today’s last reported volume for ASM INTERNATIONAL is 34220 which is 73.88% below its average volume of 131023.
More news about ASM INTERNATIONAL.
5. AZERION (AZRN.AS)
10.7% sales growth and 23.87% return on equity
Azerion Group N.V. operates a digital entertainment and media platform in the Netherlands, Germany, France, Great Britain, Ireland, Italy, other Nordic and European countries, the United States, the United Arab Emirates, and internationally. The company operates in two segments, Platform and Premium Games. Its integrated platform offers technology solutions to automate the purchase and sale of digital advertising inventory for advertisers, publishers, and game creators, as well as to develop, publish, distribute, and operate online social and casual games, and digital content. The company also operates Hawk, a digital advertising technology platform. Azerion Group N.V. was founded in 2013 and is headquartered in Schiphol-Rijk, the Netherlands.
Earnings Per Share
As for profitability, AZERION has a trailing twelve months EPS of €0.17.
PE Ratio
AZERION has a trailing twelve months price to earnings ratio of 8.65. Meaning, the purchaser of the share is investing €8.65 for every euro of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 23.87%.
More news about AZERION.
6. SANOFI (SAN.PA)
7.4% sales growth and 5.82% return on equity
Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products. In addition, it offers poliomyelitis, pertussis, and hib pediatric vaccines; influenza, booster, meningitis, and travel and endemic vaccines, which includes hepatitis A, typhoid, cholera, yellow fever, and rabies vaccines. The company also provides cough, cold, and flu, allergy, and pain care products, as well as physical, mental, and digestive wellness products; and offers products for itching, hydration, aging, cracking, overnight, and specialty skincare needs like eczema. Further, it has a collaboration and license agreement with Exscientia to develop up to 15 novel small-molecule for oncology and immunology; ABL Bio, Inc. to develop ABL301, a treatment for alpha-synucleinopathies; Blackstone Life Sciences to develop pivotal studies and clinical development program; and Seagen Inc. to design, develop, and commercialize antibody-drug conjugates for cancer. Additionally, the company has a collaboration agreement with IGM Biosciences, Inc. to develop, manufacture, and commercialize IgM antibody; Skyhawk Therapeutics, Inc to discover and develop novel small molecules; and Adagene Inc., for the discovery and development of antibody-based therapies. It also has collaborations with Scribe Therapeutics Inc. to develop genome editing technologies; and co-promotion service agreement with Provention Bio, Inc. for the commercialization of teplizumab. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was incorporated in 1994 and is headquartered in Paris, France.
Earnings Per Share
As for profitability, SANOFI has a trailing twelve months EPS of €4.3.
PE Ratio
SANOFI has a trailing twelve months price to earnings ratio of 21.15. Meaning, the purchaser of the share is investing €21.15 for every euro of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 5.82%.
Revenue Growth
Year-on-year quarterly revenue growth grew by 7.5%, now sitting on 47.08B for the twelve trailing months.
Yearly Top and Bottom Value
SANOFI’s stock is valued at €90.96 at 02:20 EST, way under its 52-week high of €104.32 and way above its 52-week low of €80.60.
Growth Estimates Quarters
The company’s growth estimates for the present quarter is a negative 5.2% and positive 0.8% for the next.
More news about SANOFI.
